-

Shareholder Alert: Robbins LLP Announces HF Foods Group, Inc. (HFFG) Sued for Misleading Shareholders

SAN DIEGO & GREENSBORO, N.C.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of HF Foods Group, Inc. (NASDAQ: HFFG) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 23, 2018 and March 23, 2020. HF Foods markets and distributes fresh produce, frozen and dry food products, and non-food products to Asian restaurants and other foodservice customers throughout the United States.

If you suffered a loss as a result of HF Foods' misconduct, click here.

HF Foods Group, Inc. (HFFG) Accused of Misleading Shareholders

According to the complaint, throughout the relevant period, HF Foods purported to disclose all of its related party transactions in its filings with the SEC, each time attesting to the Company's internal control over financial reporting and the disclosure of all fraud. Then, on June 25, 2019, HF Foods filed a Form 8-K describing its merger with B&R, failing to mention that B&R was a related party. Then, on March 23, 2020, Hindenburg Research published a report revealing that HF Foods had failed to disclose: (i) transactions with related-parties; (ii) its flagrant misuse of shareholder funds; and (iii) its gaming of the FTSE/Russell Index criteria. According to the report, "HF's massive $509 million merger with food distributor B&R appears to be a blatant undisclosed related-party transaction" and they believed "insiders are using these dozens of related-party transactions to suck cash out of the business, eventually leaving shareholders with a hollow, debt-laden company." On this news, HF Foods' stock price fell over 20% to close at $9.80 per share.

HF Foods Group, Inc. (HFFG) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Eos Energy Enterprises, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Eos Energy Enterprises, Inc. (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026. Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility-scale commercial and industrial applications. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a n...

Investor Notice: Robbins LLP Informs Investors of the Aquestive Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 and January 8, 2026. Aquestive is a pharmaceutical company committed to advancing medicines to bring improvement to patients’ lives through innovative science and delivery technologies. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a...
Back to Newsroom